“We remain very hopeful that this investigational therapy can have a transformative impact on the health of patients living with this ultra-rare, severe muscular dystrophy in the years ahead.”
Dr. Hans Lochmüller, lead investigator of REACH CDM Clinical Study & senior scientist at CHEO; Professor, Faculty of Medicine, uOttawa; uOBMRI
Dr. Hans Lochmüller, lead investigator of REACH CDM Clinical Study & senior scientist at CHEO; Professor, Faculty of Medicine, uOttawa; uOBMRI
uOBMRI’s Dr. Hanns Lochmüller recently presented promising results from a clinical trial investigating a new drug for children and youth with congenital myotonic dystrophy.
Read more about the trial results in CHEO Research Institute’s article here.